Barchart.com
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Indaptus Therapeutics Inc (INDP)

Indaptus Therapeutics Inc (INDP)
0.6600 x 15 0.6823 x 3
Pre-market by (Cboe BZX)
0.6604 -0.0599 (-8.32%) 03/24/25 [NASDAQ]
0.6600 x 15 0.6823 x 3
Pre-market 0.6980 +0.0376 (+5.69%) 07:04 ET
News & Headlines for Mon, Mar 24th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit GlobeNewswire - 5 minutes ago

INDP : 0.6604 (-8.32%)
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20 GlobeNewswire - Thu Mar 20, 7:00AM CDT

INDP : 0.6604 (-8.32%)
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab GlobeNewswire - Tue Mar 18, 7:00AM CDT

INDP : 0.6604 (-8.32%)
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update GlobeNewswire - Thu Mar 13, 6:30AM CDT

INDP : 0.6604 (-8.32%)
Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 GlobeNewswire - Wed Mar 12, 3:15PM CDT

INDP : 0.6604 (-8.32%)
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments GlobeNewswire - Tue Mar 4, 7:00AM CST

INDP : 0.6604 (-8.32%)
Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit GlobeNewswire - Tue Feb 25, 7:00AM CST

INDP : 0.6604 (-8.32%)
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 GlobeNewswire - Wed Feb 5, 7:00AM CST

INDP : 0.6604 (-8.32%)
Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules GlobeNewswire - Mon Jan 13, 7:00AM CST

INDP : 0.6604 (-8.32%)
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 GlobeNewswire - Wed Jan 8, 7:00AM CST

INDP : 0.6604 (-8.32%)

Barchart Exclusives

AXIS Capital - Value Investment Pick Barchart - 1 minute ago
Summary AXIS Capital (AXS) shows strong technical buy signals, with a Trend Seeker buy signal since 3/17 and consistent price appreciation, gaining 2.77%. The company offers diverse specialty insurance and reinsurance products globally, with notable growth in revenue and earnings expected over the next two years. Technical indicators are highly... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals
Wed, Mar 26, 2025 5:00 PM UTC
Reserve Your Spot